| abstract |
Porous silicon (pSi) microparticles (PSM) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent PSM-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies. The PSM of the present invention are also useful in developing other types of vaccines, including those not necessarily related to the treatment of cancers, such as vaccines for the treatment of acne, Alzheimer's disease, asthma, atherosclerosis, autoimmune disorders, autoinflammatory disease, celiac disease, colitis, Crohn's disease, diabetes, glomerulonephritis, infectious diseases, inflammatory bowel disease, irritable bowel syndrome, ischemia, Lupus, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, and related illnesses. |